The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Sorafenib (SOR) plus docetaxel (DOC) as first-line therapy in patients with HER2-negative metastatic breast cancer (MBC): A randomized, placebo-controlled phase II trial.
Frederik Marme
Honoraria - Sanofi
Research Funding - Bayer
Other Remuneration - Sanofi
Bernd Gerber
No relevant relationships to disclose
Marcus Schmidt
No relevant relationships to disclose
Volker Jochen Moebus
No relevant relationships to disclose
Frank Gerhard Foerster
No relevant relationships to disclose
Eva-Maria Grischke
No relevant relationships to disclose
Matthias W. Beckmann
No relevant relationships to disclose
Dirk Strumberg
No relevant relationships to disclose
Erich Solomayer
No relevant relationships to disclose
Peter Klare
No relevant relationships to disclose
Christiane Windemuth-Kieselbach
No relevant relationships to disclose
Andreas Schneeweiss
Consultant or Advisory Role - Celgene; Medac; Roche
Honoraria - AstraZeneca; Celgene; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche
Research Funding - Celgene; Roche